Ticker: PRLD

Prelude Therapeutics Incorporated (NASDAQ: PRLD) - quick status update What's happening inside: - The company remains a clinical‑stage biopharma focused on targeted cancer therapies (SMARCA degraders, KAT6A degraders, CDK9 inhibitor, precision ADCs). - Active collaborations and licensing: multi‑p...